PRESS RELEASE published on 03/30/2023 at 23:00, 3 years 1 month ago Biophytis: The Combined General Meeting will be held on second call on April 17, 2023
PRESS RELEASE published on 03/27/2023 at 08:00, 3 years 1 month ago Biophytis a présenté Sarconeos (BIO101) comme potentiel candidat médicament dans le traitement du COVID long après hospitalisation, lors du 13ème Congrès annuel International sur la Fragilité et la Sa
PRESS RELEASE published on 03/27/2023 at 08:00, 3 years 1 month ago Biophytis: Biophytis presented Sarconeos (BIO101) as a possible treatment candidate for long COVID after hospitalization during the 13th annual International Conference on Frailty and Sarcopenia Resea
PRESS RELEASE published on 03/17/2023 at 08:00, 3 years 1 month ago Biophytis announces ratio change under its American Depositary Receipt (“ADR”) program
PRESS RELEASE published on 03/17/2023 at 08:00, 3 years 1 month ago Biophytis annonce un changement de ratio pour son programme d'American Depositary Receipt ('ADR')
PRESS RELEASE published on 03/09/2023 at 08:00, 3 years 1 month ago Biophytis To Present Positive Results of Phase 2-3 COVA Study At ERS 2023 21st Lung Science Conference
PRESS RELEASE published on 03/09/2023 at 08:00, 3 years 1 month ago Biophytis présente les résultats positifs de Phase 2-3 COVA à la 21ème Conférence « Lung Science » - ERS 2023
PRESS RELEASE published on 03/02/2023 at 00:00, 3 years 2 months ago Biophytis annonce la signature d’un accord-cadre avec Intsel Chimos, laboratoire pharmaceutique qui exploitera Sarconeos (BIO101) en France pour le traitement des formes sévère de COVID-19
PRESS RELEASE published on 03/02/2023 at 00:00, 3 years 2 months ago Biophytis announces the signature of a master service agreement with Intsel Chimos, a pharmaceutical company that will operate Sarconeos (BIO101) in France for the treatment of severe forms of COVID-1
PRESS RELEASE published on 02/27/2023 at 08:00, 3 years 2 months ago Biophytis: Biophytis démarre le processus règlementaire de demande d’autorisation d’accès précoce en France auprès de la Haute Autorité de Santé (HAS) pour le traitement avec Sarconeos (BIO101) des fo
Published on 05/09/2026 at 00:00, 39 minutes ago Onco-Innovations Progresses Toward IND Preparation as Nucro-Technics Commences Bioanalysis for PNKP Inhibitor Technology
Published on 05/08/2026 at 23:00, 1 hour 39 minutes ago Digi Power X Announces Upsizing of At-the-Market Offering Program
Published on 05/08/2026 at 22:30, 2 hours 9 minutes ago Integrated BioPharma Reports Results for its Quarter Ended March 31, 2026
Published on 05/08/2026 at 22:30, 2 hours 9 minutes ago Sekur Private Data Advances Defense-Grade Secure Communications Platform
Published on 05/08/2026 at 20:38, 4 hours 1 minute ago EQS-Adhoc: thyssenkrupp nucera AG & Co. KGaA: Preliminary Figures for Q2/6M 2025/26; Order Intake Above Expectations and Previous Year ; Sales and Earnings below Market Expectations
Published on 05/08/2026 at 19:12, 5 hours 26 minutes ago EQS-Adhoc: Viromed Medical AG missed revenue forecast for 2025 financial year, but continued to grow significantly and achieved a positive result; revised forecast for 2026
Published on 05/08/2026 at 19:02, 5 hours 37 minutes ago Metall Zug – Annual General Meeting of Shareholders approves all proposals
Published on 05/07/2026 at 19:15, 1 day 5 hours ago 2026 Annual General Meeting: approval of all resolutions submitted to the Meeting
Published on 05/07/2026 at 19:15, 1 day 5 hours ago Assemblée Générale annuelle 2026 : approbation de l’ensemble des résolutions soumises au vote
Published on 05/07/2026 at 19:06, 1 day 5 hours ago Disclosure of Share Capital and Voting Rights as of April 30, 2026
Published on 05/07/2026 at 19:06, 1 day 5 hours ago Déclaration du nombre d’actions et droits de vote au 30 avril 2026
Published on 05/07/2026 at 19:00, 1 day 5 hours ago ALTAREIT - INFORMATION RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
